OrSense's non-invasive haemoglobin (Hb) monitor was the topic of a number of recent studies highlighting the clinical value of the device. Five studies, from various countries around the world, will be presented as posters at the AABB Annual Meeting and CTTXPO 2012, held in Boston, MA on 6th to 9th October 2012, and two were presented in the DGTI Annual Congress held at Graz, Austria in September. In addition, two studies were recently published in the peer-reviewed journals Transfusion and the Journal of Maternal-Fetal and Neonatal Medicine. All studies conclude that OrSense's non-invasive Hb monitor is reliable, accurate, easy to use and favourably accepted by both staff and subjects.
The studies were conducted independently by groups from Central Institute for Blood Transfusion and Immunology, Innsbruck, Austria; State University of Campinas, Brazil; the Madrid Red Cross, Spain; Haema AG, Leipzig, and Deutsche Gesellschaft fÃ¼r Humanplasma Krefeld, both from Germany; South Korea Yonsei University and Hanmaum Blood Center; Assaf Harofe Hospital, Israel; and Rabin Medical Center, Israel. Most of the studies were conducted in order to assess OrSense's non-invasive Hb monitor for prescreening blood donors for anaemia. The studies conclude that OrSense's device is comparable with invasive, point-of-care Hb monitoring systems in terms of accuracy and reliability, and is superior to invasive systems since it reduces risk of infection and eliminates the need for painful finger pricking.
According to the study by the group of Dr Vagner Castro from the University of Campinas, Brazil, published in Transfusion, the results obtained suggest that the OrSense monitor is more precise than the prevalent invasive point-of-care device in preventing anaemic donors from donating. In addition, the study performed by the Spanish group, led by Dr Emma Castro, from the Spanish Red Cross Transfusion Center in Madrid, assessed for the first time the impact of the non-invasive Hb monitoring experience on both staff and subjects in a blood bank facility. The researchers suggested that "procuring a better experience for blood donors may undisputedly facilitate repetition."
OrSense's non-invasive Hb measurement reportedly has a number advantages including the prevention of pain and potential transmission of infectious diseases, a reduced need for trained personnel, short measurement time and the absence of bio-hazardous waste. It is a non-invasive system for accurate and quick Hb measurements. The portable, wireless device operates via rechargeable batteries using a ring-shaped sensor that is fitted on the donor's finger and applies pressure, temporarily occluding local blood flow. During the occlusion, optical elements in the sensor perform a sensitive measurement of the light transmitted through the finger. This technology, called SpectOLight, provides an accurate measurement of the donor's blood constituents, while greatly improving donors' comfort, eliminating infection risk and providing the medical staff with accurate readings and immediate results.
OrSense will launch Glasswing, its next-generation, wireless, non-invasive Hb measurement system for anaemia monitoring, haemorrhage detection and pre-donation, during the AABB meeting. The portable, wireless system enables online storage and download of data, real-time communication with electronic medical records in the hospital or blood donation centres as well as with other digital data devices and printers. The device is suited for use in a variety of clinical environments, including peri-operative and critical care, emergency medicine, blood donation facilities, women's health, primary care physician's office and homecare. Glasswing is pending FDA 510(k) clearance.